Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Perceptual adaptation after cochlear implantation

Official title: Evaluation of Frequency Allocation Tables for Recently Implanted Single-Sided Deaf Cochlear Implant Users

Run by NYU Langone Health · NCT07039435 · Data updated 2026-11-12

This trial will try different frequency maps in adults who just received a cochlear implant in one ear to see which map improves sound quality, device use, and speech understanding.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment22 (estimated)
SponsorNYU Langone Health
Academic / other
Locations1 site (New York, New York)
StatusRecruiting
StartedJanuary 4, 2024
Main results expectedJuly 31, 2028
Study endsJuly 31, 2029
Registry record updatedJuly 7, 2026
Trial IDNCT07039435 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) who are English-speaking, have normal or minimal hearing in the non-implanted ear, intend to receive or have just received a unilateral cochlear implant that has not yet been activated, and have no known ear anatomical abnormalities.

Probably not a fit

People with significant hearing loss in the contralateral ear, documented anatomical abnormalities of the implanted ear, non-English speakers, or long-term implant users with stable mappings are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Newly implanted single-sided deaf cochlear implant (SSD-CI) users will be given four different frequency maps during the first month after device activation, with one map reflecting standard clinical settings and three maps shifted to reduce place-pitch mismatch. Participants will alternate which map they use daily during the first month (with occasional allowed exceptions), then each week will compare all four maps and choose which to use for the following week. Outcomes include subjective sound quality, patterns of device use, and objective speech perception measures. The protocol targets adults with normal or minimal hearing in the opposite ear and excludes those with anatomical abnormalities or significant contralateral hearing loss.

Why it matters

Potential benefit: If successful, the approach could yield better perceived sound quality and improved speech understanding for single-sided deaf cochlear implant users by identifying more comfortable and effective frequency mappings.

How similar studies have gone: Prior small studies and clinical reports have suggested that remapping to reduce place-pitch mismatch can improve sound quality and sometimes speech perception, but findings across studies have been variable and further data are needed.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age 18 or older
2. No known anatomical abnormalities in either ear
3. English speaking
4. Intends to receive a cochlear implant in one ear (or has already received it but it has not been activated).
5. Normal hearing (or minimal hearing loss) in the contralateral ear

Exclusion Criteria:

1. Under age 18
2. Documented anatomical abnormality of the implanted ear
3. Non-English speaking
4. Greater than minimal hearing loss in the contralateral ear.

Where it's running

  • NYU Langone Health
    New York, New York, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.